Investment Rating - The report maintains an "Accumulate" rating for the company [7] Core Views - The steel industry is experiencing improved profitability, leading to a sequential improvement in the company's performance for Q1 2025. The company reported revenue of 8.375 billion RMB, a year-on-year decrease of 8.21% and a quarter-on-quarter decrease of 8.11%. However, the net profit attributable to the parent company was 137 million RMB, showing a year-on-year decrease of 19.84% but a quarter-on-quarter increase of 143.36% [1][2] - The company is actively pursuing cost-saving measures and enhancing the differentiation and high-end nature of its casting pipe products. It is also increasing its market share in new products and markets, while steadily raising the proportion of special steel products [2] - The report indicates that the steel industry's supply-side optimization is gradually approaching, which is expected to further improve profitability in the sector [3] Summary by Sections Financial Performance - In Q1 2025, the company's total operating costs decreased by 10.74% year-on-year, which is greater than the revenue decline of 8.21%. This resulted in an increase in the sales gross margin by 2.77 percentage points to 7.61%. The net profit margin also increased by 6.81 percentage points to 1.83% due to improvements in various period expenses [2] - The report forecasts the company's earnings per share (EPS) for 2025-2027 to be 0.18, 0.24, and 0.26 RMB respectively, with book value per share (BVPS) projected at 6.57, 6.74, and 6.90 RMB [4] Market Conditions - The average sales profit margin for key enterprises in the steel industry was 0.71% in 2024, a year-on-year decrease of 0.63 percentage points. The government has been emphasizing strict control over steel production to prevent excessive competition, indicating a potential restart of supply-side optimization [3] - The report predicts that the global iron ore production capacity will continue to expand in 2025, which may lead to a further decline in iron ore prices and an overall recovery in steel industry profits [3] Valuation - The target price for the company is set at 3.98 RMB, based on a price-to-earnings (PE) ratio of 0.61X for 2025, which is higher than the average PE of comparable companies at 0.52X [4][8]

Investment Rating - The investment rating for the company is maintained at "Buy" with a target price of RMB 328.30 [7][8]. Core Views - The company reported a revenue of RMB 367.26 billion and a net profit attributable to the parent company of RMB 116.68 billion for 2024, reflecting a year-on-year growth of 5.1% and 0.7% respectively. The profit was below market expectations due to delays in domestic equipment upgrade policies [1]. - The company is expected to achieve steady growth in 2025, driven by the acceleration of domestic equipment upgrade policies and ongoing efforts in product promotion both domestically and internationally [1]. - The company’s three core business segments are projected to perform well in 2025: 1. IVD segment revenue reached RMB 137.65 billion in 2024, with a year-on-year increase of 10.8% and strong overseas growth [2]. 2. Medical imaging segment revenue was RMB 74.98 billion, up 6.6% year-on-year, supported by the launch of high-end products [2]. 3. Life information and support segment revenue was RMB 135.57 billion, down 11.1% year-on-year, but expected to rebound in 2025 due to improving domestic policies [2]. Summary by Sections Financial Performance - The company’s revenue for 1Q25 was RMB 82.37 billion, with a net profit of RMB 26.29 billion, showing a year-on-year decline of 12.1% and 16.8% respectively, but a quarter-on-quarter increase of 13.8% and 154.9% [1]. - The company’s revenue forecast for 2025 is RMB 40.545 billion, with a projected net profit of RMB 12.84 billion, reflecting a growth of 10.04% [6]. Market Expansion - The company’s overseas revenue reached RMB 164.34 billion in 2024, growing by 21.3%, with significant contributions from the Asia-Pacific and European regions [3]. - Domestic revenue was RMB 202.92 billion, down 5.1% year-on-year, but expected to improve in 2025 due to the release of medical infrastructure orders and enhanced competitiveness [3]. Profitability and Valuation - The EPS forecast for 2025 is adjusted to RMB 10.59, with a PE ratio of 31x for 2025, leading to a target price of RMB 328.30 [4]. - The company is recognized as a leading domestic medical device manufacturer with strong brand influence and a continuously improving global sales network [4].

证券研究报告 锦浪科技 (300763 CH) 去库影响需求，电站业务表现亮眼 | 华泰研究 | | | 年报点评 | | --- | --- | --- | --- | | 2025 年 | 4 月 | 29 日│中国内地 | 电力设备与新能源 | 公司 24 年收入 65.42 亿元，同比+7.23%，归母净利 6.91 亿元，同比 -11.32%，扣非净利 6.37 亿元，同比-18.94%，归母净利低于我们此前 11.55 亿的预期，主要系海外光储去库影响需求；25Q1 收入 15.18 亿元，同比 +8.65%，归母净利 1.95 亿元，同/环比+860%/+774%，主要系电站收入同 比提升。公司位列逆变器第一梯队产品力突出，维持"增持"评级。 24Q4 业绩受去库拖累，25Q1 电站收入拉动增长 公司 24Q4 收入 13.81 亿元，同/环比-5.40%/-23.57%，归母净利 0.22 亿 元，同/环比-19.99%/-92.96%，主要系海外去库拖累。公司 24Q4 毛利率/ 净利率达 23.72%/1.61%，环比-12.71/-15.91pct，24Q4 期间费用率达 21.78%， ...

Investment Rating - The report maintains a rating of "Buy" for the company [7] Core Views - The company experienced significant revenue growth in 2024, achieving 6.522 billion RMB, a year-on-year increase of 31.27%, but reported a net loss of 239 million RMB [1][2] - In Q1 2025, the company showed a strong recovery with revenue of 1.981 billion RMB, a year-on-year increase of 113% [1][2] - The company is focusing on its core business while actively seeking diversification, particularly in high-performance copper wire and renewable energy sectors [3] Summary by Sections Financial Performance - The company's gross profit margin for 2024 was 2.01%, down 3.82 percentage points year-on-year, but improved significantly in Q1 2025 with a gross margin of 4.65% [2] - The net profit margin for Q1 2025 was 1.15%, reflecting a year-on-year increase of 6.33 percentage points [2] - The company’s operating expenses decreased slightly in 2024, with a total expense ratio of 4.7% [2] Business Strategy - The company is enhancing its production capacity in advanced copper foil, reaching an annual capacity of over 110,000 tons, positioning itself as an industry leader [3] - It is also expanding into new business areas, including high-purity copper technologies and renewable energy projects, such as solar and wind energy [3] Earnings Forecast and Valuation - The company’s earnings per share (EPS) for 2025 is projected at 0.27 RMB, with subsequent years expected to rise to 0.61 RMB in 2026 and 0.96 RMB in 2027 [4] - The target price for the company is set at 21.04 RMB, based on a price-to-book (PB) ratio of 1.28 for 2025 [4][8]

Investment Rating - The report maintains a "Buy" rating for the company with a target price of 15.54 RMB [6][4]. Core Insights - The company reported Q1 2025 revenue of 2.992 billion RMB, a year-over-year increase of 3.66% but a quarter-over-quarter decrease of 4.41%. The net profit attributable to the parent company was 168 million RMB, reflecting a year-over-year increase of 178.09% and a quarter-over-quarter increase of 47.24% [1][2]. - The rise in rare earth prices is expected to benefit the company's performance, alongside its proactive overseas resource acquisition strategy to enhance raw material self-sufficiency [1][4]. - The average rare earth price index for Q1 2025 was 176.29, showing a year-over-year increase of 5.95% and a quarter-over-quarter increase of 2.95% [2]. Summary by Sections Financial Performance - In Q1 2025, the company sold 3,591 tons of rare earth oxides, 3,499 tons of rare earth salts, and 4,823 tons of rare earth metals, with year-over-year changes of +40.25%, -43.3%, and +44.49% respectively [2]. - The gross profit margin increased by 7.88 percentage points to 7.98% due to a reduction in operating costs by 4.52% [2]. Market Outlook - The supply-demand relationship for rare earths is expected to improve in 2025, with a projected global supply shortage of 5.8% for praseodymium and neodymium oxides in 2025 and 4.6% in 2026 [3]. - The strategic importance of rare earths is highlighted, with potential price stability anticipated due to reduced imports from Myanmar and domestic regulatory measures [3]. Valuation Metrics - The company’s earnings per share (EPS) estimates for 2025, 2026, and 2027 are projected to be 0.45 RMB, 0.61 RMB, and 0.70 RMB respectively [4]. - The report assigns a price-to-earnings (PE) ratio of 34.5x for 2025, aligning with the average of comparable companies [4][11].

Investment Rating - The report maintains a "Buy" rating for the company with a target price of RMB 81.80 [8][9]. Core Insights - The company achieved stable revenue and net profit growth in Q1 2025, with revenues of RMB 6.99 billion and net profit of RMB 1.61 billion, reflecting year-on-year increases of 12.8% and 12.2% respectively [1]. - Domestic revenue in 2024 was RMB 13.82 billion, a modest increase of 2.1%, while overseas revenue reached RMB 13.59 billion, growing by 30.4%, indicating a strong international market performance [2]. - The company is positioned as a leading domestic endoscope consumables provider, with expectations for accelerated growth post-collection impact [5]. Summary by Sections Financial Performance - In 2024, the company reported total revenue of RMB 27.55 billion, with a net profit attributable to the parent company of RMB 5.53 billion, marking increases of 14.3% and 13.9% year-on-year respectively [1]. - The gross margin for domestic sales improved to 68.7%, up by 3.2 percentage points, while overseas gross margin was 66.8%, an increase of 3.3 percentage points [2]. Product Line Performance - Revenue from endoscopic consumables and tumor intervention products grew by 13.5% and 19.1% respectively, while visualization products saw a significant decline of 46.2% due to collection impacts [3]. Cost Structure - The report indicates a decrease in financial expense ratio in Q1 2025, with sales, management, and R&D expense ratios showing varied changes, reflecting the company's ongoing investment in market expansion [4]. Earnings Forecast - The forecast for net profit attributable to the parent company for 2025-2027 is RMB 6.68 billion, RMB 7.84 billion, and RMB 9.08 billion respectively, with year-on-year growth rates of 20.8%, 17.5%, and 15.8% [5][7].

证券研究报告 比音勒芬 (002832 CH) 营收稳步增长，盈利能力短期承压 华泰研究 年报点评 2025 年 4 月 29 日│中国内地 服装 比音勒芬发布 2024 年报及 1Q25 业绩：2024 年公司实现营收 40.0 亿元 （yoy+13.2%），归母净利润 7.8 亿元（yoy-14.3%），低于我们此前预期（9.1 亿元），主因消费环境仍处于弱复苏，线下渠道毛利承压明显。1Q25 营收 12.9 亿元（yoy+1.4%），归母净利润 3.3 亿元（yoy-8.5%）。利润分配方面， 24 全年拟派息 0.5 元/股，分红率约 36.6%。公司盈利短期相对承压，但营 收在消费复苏尚不确定的环境下仍保持同业领先的稳健增长，叠加定位高端 消费人群的用户壁垒以及海外品牌 KENT&CURWEN 开启第二增长曲线等 优势，维持"买入"评级。 全品类、全渠道协同发展，共同驱动公司营收增长 分品类来看，上装、外套、下装收入分别同比+13.1%/17.5%/6.3%至 17.1/11.6/7.5 亿元，占营收比重分别为 42.8%/28.8%18.8%。上装作为核心 品类，凭借其丰富的款式设计与优质面料，持 ...

Investment Rating - The investment rating for the company is "Buy" with a target price of 80.82 RMB [7][8]. Core Views - The company reported a revenue of 5.35 billion RMB in Q1 2025, representing a year-over-year increase of 12.3%, while the net profit attributable to the parent company was 760 million RMB, down 3.3% year-over-year. The short-term pressure on profitability is attributed to the ramp-up of new factory capacity. However, the company is expected to benefit from capacity improvements and the expansion of new customers, maintaining its competitive advantage [1][5]. - The company has strategically expanded its customer base, including partnerships with Adidas, New Balance, and On, which have significantly contributed to revenue growth. The company anticipates further impressive growth as the peak season approaches in Q2 2025 [2][5]. - The company's net profit margin decreased by 2.3 percentage points year-over-year to 14.2%, and the gross profit margin fell by 5.5 percentage points to 22.9%, primarily due to the initial efficiency ramp-up of new factories. The workforce increased to 184,000, a 17% year-over-year rise. The company’s inventory was 3.67 billion RMB, up 12.5% year-over-year, and accounts receivable reached 3.31 billion RMB, up 15.3% year-over-year, indicating a focus on stocking for production expansion [3][5]. - The company acquired three Vietnamese shoe companies for a total of approximately 67.4 million RMB to optimize production resources, which are expected to enhance production capacity synergy within 1-2 years, thereby increasing the company's market share in global footwear manufacturing [4][5]. - The profit forecast for 2025-2027 is maintained at 4.32 billion RMB, 4.95 billion RMB, and 5.61 billion RMB, respectively. The company is assigned a PE ratio of 21.8 for 2025, based on a comparable company average PE of 12.7, reflecting its strong customer base and industry leadership [5][6]. Summary by Sections Financial Performance - Q1 2025 revenue was 5.35 billion RMB, a 12.3% increase year-over-year, while net profit was 760 million RMB, a decrease of 3.3% year-over-year [1]. - The company’s net profit margin decreased to 14.2%, and gross profit margin fell to 22.9% due to new factory ramp-up [3]. Customer Expansion - The company has successfully expanded its customer base, notably with Adidas, New Balance, and On, contributing to an 8.24% increase in sneaker sales volume to 49 million pairs in Q1 2025 [2]. Capacity and Acquisitions - The company acquired three Vietnamese shoe companies to enhance production capacity, expected to yield benefits within 1-2 years [4]. Profit Forecast and Valuation - The profit forecast for 2025-2027 is set at 4.32 billion RMB, 4.95 billion RMB, and 5.61 billion RMB, with a target PE ratio of 21.8 for 2025 [5][6].

Investment Rating - The investment rating for the company is "Buy" [6][4]. Core Views - The company has shown stable growth in Q1 2025, with revenue, net profit attributable to the parent, and net profit excluding non-recurring items reaching 230 million, 58 million, and 53 million RMB respectively, representing year-on-year increases of 3.6%, 5.2%, and 7.8% [1]. - The rapid growth of overseas revenue has become a significant source of income, with overseas revenue in 2024 reaching 350 million RMB, a year-on-year increase of 78.3%, accounting for 43.8% of total revenue [2]. - The company is expected to recover its performance growth in 2025, driven by improvements in domestic business and continued expansion in overseas markets [2]. Summary by Sections Financial Performance - In Q1 2025, the company maintained a gross margin of 66.69%, although it decreased by 7.15 percentage points year-on-year due to the impact of centralized procurement [3]. - The company has successfully controlled its sales and R&D expense ratios, which decreased year-on-year [3]. Profit Forecast - The profit forecast for the company estimates net profits attributable to the parent company for 2025, 2026, and 2027 to be 240 million, 290 million, and 340 million RMB respectively, with growth rates of 90%, 21%, and 20% [4]. - The estimated EPS for 2025, 2026, and 2027 is projected to be 0.62, 0.75, and 0.90 RMB respectively [4]. Valuation - The company is assigned a target price of 18.59 RMB for A-shares and 11.34 HKD for H-shares, based on a PE valuation of 30x for A-shares and 17x for H-shares in 2025 [4][6].

证券研究报告 瑞丰银行 (601528 CH) 资产平稳扩张，成本费用优化 | 华泰研究 | | | 季报点评 | | --- | --- | --- | --- | | 2025 年 | 4 月 | 29 日│中国内地 | 区域性银行 | 瑞丰银行 2025 年 1-3 月归母净利润、营业收入分别同比+6.7%、+5.1%， 增速分别较 2024 年-4.6pct、-10.2pct。1-3 月年化 ROE、ROA 分别同比 -0.46pct、-0.04pct 至 8.96%、0.76%。Q1 主要亮点包括：息差韧性凸显， 账面不良率保持平稳、拨备水平提升；而其他非息增速有所回落。我们认为 公司战略转型切实有效、业务拓展空间广阔，维持买入评级。 信贷结构优化，息差韧性凸显 3 月末总资产、贷款、存款增速分别为+11.1%、+11.7%、+13.7%，分别较 24 年末-0.9pct、-3.8pct、+0.8pct，开门红营销前置后 Q1 信贷投放增速放 缓，但结构较优。Q1 净新增贷款 58 亿元，其中零售/对公/票据分别占 6%/86%/9%。净息差较 24A 下行 4bp 至 1.46%，年初重定价压力下 ...